Genetically modified human CD4+ T cells can be evaluated in vivo without lethal graft-versus-host disease

Riyasat Ali, Jeffrey Babad, Antonia Follenzi, John A. Gebe, Michael A. Brehm, Gerald T. Nepom, Leonard D. Shultz, Dale L. Greiner, Teresa P. DiLorenzo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Adoptive cell immunotherapy for human diseases, including the use of T cells modified to express an anti-tumour T-cell receptor (TCR) or chimeric antigen receptor, is showing promise as an effective treatment modality. Further advances would be accelerated by the availability of a mouse model that would permit human T-cell engineering protocols and proposed genetic modifications to be evaluated in vivo. NOD-scid IL2rγnull (NSG) mice accept the engraftment of mature human T cells; however, long-term evaluation of transferred cells has been hampered by the xenogeneic graft-versus-host disease (GVHD) that occurs soon after cell transfer. We modified human primary CD4+ T cells by lentiviral transduction to express a human TCR that recognizes a pancreatic beta cell-derived peptide in the context of HLA-DR4. The TCR-transduced cells were transferred to NSG mice engineered to express HLA-DR4 and to be deficient for murine class II MHC molecules. CD4+ T-cell-depleted peripheral blood mononuclear cells were also transferred to facilitate engraftment. The transduced cells exhibited long-term survival (up to 3 months post-transfer) and lethal GVHD was not observed. This favourable outcome was dependent upon the pre-transfer T-cell transduction and culture conditions, which influenced both the kinetics of engraftment and the development of GVHD. This approach should now permit human T-cell transduction protocols and genetic modifications to be evaluated in vivo, and it should also facilitate the development of human disease models that incorporate human T cells.

Original languageEnglish (US)
Pages (from-to)339-351
Number of pages13
JournalImmunology
Volume148
Issue number4
DOIs
StatePublished - Aug 1 2016

Fingerprint

Graft vs Host Disease
T-Lymphocytes
T-Cell Antigen Receptor
HLA-DR4 Antigen
Genetic Transduction
Cell Engineering
Adoptive Immunotherapy
Antigen Receptors
Insulin-Secreting Cells
Human Development
Blood Cells
Cell Culture Techniques
Peptides
Survival

Keywords

  • human CD4 T cells
  • immunodeficient mice
  • lentiviral transduction

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Genetically modified human CD4+ T cells can be evaluated in vivo without lethal graft-versus-host disease. / Ali, Riyasat; Babad, Jeffrey; Follenzi, Antonia; Gebe, John A.; Brehm, Michael A.; Nepom, Gerald T.; Shultz, Leonard D.; Greiner, Dale L.; DiLorenzo, Teresa P.

In: Immunology, Vol. 148, No. 4, 01.08.2016, p. 339-351.

Research output: Contribution to journalArticle

Ali, R, Babad, J, Follenzi, A, Gebe, JA, Brehm, MA, Nepom, GT, Shultz, LD, Greiner, DL & DiLorenzo, TP 2016, 'Genetically modified human CD4+ T cells can be evaluated in vivo without lethal graft-versus-host disease', Immunology, vol. 148, no. 4, pp. 339-351. https://doi.org/10.1111/imm.12613
Ali, Riyasat ; Babad, Jeffrey ; Follenzi, Antonia ; Gebe, John A. ; Brehm, Michael A. ; Nepom, Gerald T. ; Shultz, Leonard D. ; Greiner, Dale L. ; DiLorenzo, Teresa P. / Genetically modified human CD4+ T cells can be evaluated in vivo without lethal graft-versus-host disease. In: Immunology. 2016 ; Vol. 148, No. 4. pp. 339-351.
@article{15b633757d40417091086ef46c8437a6,
title = "Genetically modified human CD4+ T cells can be evaluated in vivo without lethal graft-versus-host disease",
abstract = "Adoptive cell immunotherapy for human diseases, including the use of T cells modified to express an anti-tumour T-cell receptor (TCR) or chimeric antigen receptor, is showing promise as an effective treatment modality. Further advances would be accelerated by the availability of a mouse model that would permit human T-cell engineering protocols and proposed genetic modifications to be evaluated in vivo. NOD-scid IL2rγnull (NSG) mice accept the engraftment of mature human T cells; however, long-term evaluation of transferred cells has been hampered by the xenogeneic graft-versus-host disease (GVHD) that occurs soon after cell transfer. We modified human primary CD4+ T cells by lentiviral transduction to express a human TCR that recognizes a pancreatic beta cell-derived peptide in the context of HLA-DR4. The TCR-transduced cells were transferred to NSG mice engineered to express HLA-DR4 and to be deficient for murine class II MHC molecules. CD4+ T-cell-depleted peripheral blood mononuclear cells were also transferred to facilitate engraftment. The transduced cells exhibited long-term survival (up to 3 months post-transfer) and lethal GVHD was not observed. This favourable outcome was dependent upon the pre-transfer T-cell transduction and culture conditions, which influenced both the kinetics of engraftment and the development of GVHD. This approach should now permit human T-cell transduction protocols and genetic modifications to be evaluated in vivo, and it should also facilitate the development of human disease models that incorporate human T cells.",
keywords = "human CD4 T cells, immunodeficient mice, lentiviral transduction",
author = "Riyasat Ali and Jeffrey Babad and Antonia Follenzi and Gebe, {John A.} and Brehm, {Michael A.} and Nepom, {Gerald T.} and Shultz, {Leonard D.} and Greiner, {Dale L.} and DiLorenzo, {Teresa P.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/imm.12613",
language = "English (US)",
volume = "148",
pages = "339--351",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Genetically modified human CD4+ T cells can be evaluated in vivo without lethal graft-versus-host disease

AU - Ali, Riyasat

AU - Babad, Jeffrey

AU - Follenzi, Antonia

AU - Gebe, John A.

AU - Brehm, Michael A.

AU - Nepom, Gerald T.

AU - Shultz, Leonard D.

AU - Greiner, Dale L.

AU - DiLorenzo, Teresa P.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Adoptive cell immunotherapy for human diseases, including the use of T cells modified to express an anti-tumour T-cell receptor (TCR) or chimeric antigen receptor, is showing promise as an effective treatment modality. Further advances would be accelerated by the availability of a mouse model that would permit human T-cell engineering protocols and proposed genetic modifications to be evaluated in vivo. NOD-scid IL2rγnull (NSG) mice accept the engraftment of mature human T cells; however, long-term evaluation of transferred cells has been hampered by the xenogeneic graft-versus-host disease (GVHD) that occurs soon after cell transfer. We modified human primary CD4+ T cells by lentiviral transduction to express a human TCR that recognizes a pancreatic beta cell-derived peptide in the context of HLA-DR4. The TCR-transduced cells were transferred to NSG mice engineered to express HLA-DR4 and to be deficient for murine class II MHC molecules. CD4+ T-cell-depleted peripheral blood mononuclear cells were also transferred to facilitate engraftment. The transduced cells exhibited long-term survival (up to 3 months post-transfer) and lethal GVHD was not observed. This favourable outcome was dependent upon the pre-transfer T-cell transduction and culture conditions, which influenced both the kinetics of engraftment and the development of GVHD. This approach should now permit human T-cell transduction protocols and genetic modifications to be evaluated in vivo, and it should also facilitate the development of human disease models that incorporate human T cells.

AB - Adoptive cell immunotherapy for human diseases, including the use of T cells modified to express an anti-tumour T-cell receptor (TCR) or chimeric antigen receptor, is showing promise as an effective treatment modality. Further advances would be accelerated by the availability of a mouse model that would permit human T-cell engineering protocols and proposed genetic modifications to be evaluated in vivo. NOD-scid IL2rγnull (NSG) mice accept the engraftment of mature human T cells; however, long-term evaluation of transferred cells has been hampered by the xenogeneic graft-versus-host disease (GVHD) that occurs soon after cell transfer. We modified human primary CD4+ T cells by lentiviral transduction to express a human TCR that recognizes a pancreatic beta cell-derived peptide in the context of HLA-DR4. The TCR-transduced cells were transferred to NSG mice engineered to express HLA-DR4 and to be deficient for murine class II MHC molecules. CD4+ T-cell-depleted peripheral blood mononuclear cells were also transferred to facilitate engraftment. The transduced cells exhibited long-term survival (up to 3 months post-transfer) and lethal GVHD was not observed. This favourable outcome was dependent upon the pre-transfer T-cell transduction and culture conditions, which influenced both the kinetics of engraftment and the development of GVHD. This approach should now permit human T-cell transduction protocols and genetic modifications to be evaluated in vivo, and it should also facilitate the development of human disease models that incorporate human T cells.

KW - human CD4 T cells

KW - immunodeficient mice

KW - lentiviral transduction

UR - http://www.scopus.com/inward/record.url?scp=84978533698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978533698&partnerID=8YFLogxK

U2 - 10.1111/imm.12613

DO - 10.1111/imm.12613

M3 - Article

C2 - 27124592

AN - SCOPUS:84978533698

VL - 148

SP - 339

EP - 351

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 4

ER -